Home

A BRIAN DAVIS

CIK 1184432 · Chief Financial Officer · last filed 2026-01-12

A BRIAN DAVIS is a Chief Financial Officer who has filed 20 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for GRCE, was dated Jan 12, 2026. Across all open-market trades the lifetime net is +$98.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$7.0K

Companies

6

Total Filings

20

Lifetime Open-Market Net

$98.7K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GRCE Director — $2.25 — $0 2 2026-01-12
Grace Therapeutics, Inc. (ACST) Delisted Director — $3.37 — $0 1 2023-12-20
VRCA Chief Financial Officer 1,290 $5.40 $7.0K $98.7K 5 2021-06-07
Strongbridge Biopharma plc (SBBP) Delisted Chief Financial Officer 33,366 $2.00 $66.7K $0 3 2019-02-22
TENGION INC (TNGN) Delisted Chf. Fin. Offr, VP Fin. 9,167 — — $0 3 2012-02-21
NEOSE TECHNOLOGIES INC (NTEC) Delisted Sr. Vice President and CFO 33,650 $9.63 $324.0K $0 5 2008-02-05

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-12 GRCE Grant (A) — $0 EDGAR
2025-05-13 GRCE Grant (A) — $0 EDGAR
2023-12-20 Grace Therapeutics, Inc. (ACST) Delisted Grant (A) — $0 EDGAR
2021-06-07 VRCA Buy (P) +5,000 $49.5K EDGAR
2021-03-03 VRCA Grant (A) — $0 EDGAR
2020-08-17 VRCA Buy (P) +7,900 $49.3K EDGAR
2020-03-02 VRCA Grant (A) — $0 EDGAR
2019-10-21 VRCA Grant (A) — $0 EDGAR
2019-02-22 Strongbridge Biopharma plc (SBBP) Delisted Grant (A) +20,000 $0 EDGAR
2018-02-28 Strongbridge Biopharma plc (SBBP) Delisted Tax (F) −8,696 -$57.4K EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.